163
Participants
Start Date
September 30, 2014
Primary Completion Date
October 25, 2024
Study Completion Date
March 11, 2026
Regorafenib
For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
Placebo
For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
Institut Paoli Calmettes, Marseille
La Timone University Hospital, Marseille
Centre Francois Baclesse, Caen
Centre Georges Francois Leclerc, Dijon
Hopital Jean Monjoz, Besançon
Institut Claudius Regaud, Toulouse
Institut Bergonie, Bordeaux
ICM Val d'Aurelle, Montpellier
Centre Eugene Marquis, Rennes
CHU Bretonneau, Tours
Institut de Cancérologie Lucien Neuwirth (ICLN), Saint-Priest-en-Jarez
Institut de cancerologie de l'ouest site Rene Gauducheau, Saint-Herblain
Institut de cancerologie de lorraine alexis Vautrin, Vandœuvre-lès-Nancy
Centre Oscar Lambret, Lille
Centre Léon Berard, Lyon
Hôpital Cochin, Paris
Gustave Roussy, Villejuif
Centre Antoine Lacassagne, Nice
Institut Curie, Paris
UNICANCER
OTHER